| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/07/2026 | ±3.4% | +2.5% | over-priced |
| 02/06/2026 | ±4.8% | +3.4% | over-priced |
| 11/06/2025 | ±2.1% | +6.9% | under-priced |
| 08/07/2025 | ±1.8% | +6.8% | under-priced |
| 02/07/2025 | ±2.7% | -1.0% | over-priced |
| 11/07/2024 | ±2.5% | -5.3% | under-priced |
| 08/08/2024 | ±3.8% | +2.6% | over-priced |
| 02/08/2024 | ±2.3% | -2.5% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2027 | — | $1.5B | $201M |
| Q4 FY2026 | $2.24 | $1.6B | $220M |
| Q3 FY2026 | $1.96 | $1.5B | $194M |
| Q2 FY2026 | $1.94 | $1.5B | $193M |
STERIS plc (STE) reports in 100 days, with the next report estimated for 12/21/2026. Across the last 8 reports, options priced an average ±2.9% earnings move while the stock actually moved 3.9% on average — the market has been roughly fair on STE's earnings risk. Fundamentals into the print: EPS up 0.0% year-over-year, revenue up 7.3%. QuantLogix's live 5-factor engine currently reads STE as a underweight at 38/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →